关注
N. Arvind Dasari
N. Arvind Dasari
其他姓名Dasari A, N. Arvind Dasri
University of Texas MD Anderson Cancer Center
在 mdanderson.org 的电子邮件经过验证
标题
引用次数
引用次数
年份
Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States
A Dasari, C Shen, D Halperin, B Zhao, S Zhou, Y Xu, T Shih, JC Yao
JAMA oncology 3 (10), 1335-1342, 2017
29952017
Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer
S Kopetz, J Desai, E Chan, JR Hecht, PJ O'Dwyer, D Maru, V Morris, ...
Journal of clinical oncology 33 (34), 4032, 2015
7392015
Disparity of race reporting and representation in clinical trials leading to cancer drug approvals from 2008 to 2018
JM Loree, S Anand, A Dasari, JM Unger, A Gothwal, LM Ellis, ...
JAMA oncology 5 (10), e191870-e191870, 2019
4212019
Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study
DM Halperin, C Shen, A Dasari, Y Xu, Y Chu, S Zhou, YCT Shih, JC Yao
The Lancet Oncology 18 (4), 525-534, 2017
3642017
Classifying colorectal cancer by tumor location rather than sidedness highlights a continuum in mutation profiles and consensus molecular subtypes
JM Loree, AAL Pereira, M Lam, AN Willauer, K Raghav, A Dasari, ...
Clinical Cancer Research 24 (5), 1062-1072, 2018
3232018
Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment
MP Morelli, MJ Overman, A Dasari, SMA Kazmi, T Mazard, E Vilar, ...
Annals of Oncology 26 (4), 731-736, 2015
2802015
Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors
AW Tolcher, WA Messersmith, SM Mikulski, KP Papadopoulos, EL Kwak, ...
Journal of clinical oncology 30 (19), 2348, 2012
2732012
ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal–Anal Task Forces whitepaper
A Dasari, VK Morris, CJ Allegra, C Atreya, AB Benson III, P Boland, ...
Nature reviews Clinical oncology 17 (12), 757-770, 2020
2722020
Oxidative stress induces premature senescence by stimulating caveolin-1 gene transcription through p38 mitogen-activated protein kinase/Sp1–mediated activation of two GC-rich …
A Dasari, JN Bartholomew, D Volonte, F Galbiati
Cancer research 66 (22), 10805-10814, 2006
2532006
Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: a SEER database analysis of 162,983 cases
A Dasari, K Mehta, LA Byers, H Sorbye, JC Yao
Cancer 124 (4), 807-815, 2018
2232018
A Phase I, dose-finding study in patients with advanced solid malignancies of the oral γ-secretase inhibitor PF-03084014
WA Messersmith, GI Shapiro, JM Cleary, A Jimeno, A Dasari, B Huang, ...
Clinical Cancer Research 21 (1), 60-67, 2015
2232015
Digital health for optimal supportive care in oncology: benefits, limits, and future perspectives
M Aapro, P Bossi, A Dasari, L Fallowfield, P Gascón, M Geller, K Jordan, ...
Supportive care in cancer 28, 4589-4612, 2020
2122020
Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge
CM Parseghian, JM Loree, VK Morris, X Liu, KK Clifton, S Napolitano, ...
Annals of Oncology 30 (2), 243-249, 2019
1992019
Epidemiology, incidence, and prevalence of neuroendocrine neoplasms: are there global differences?
S Das, A Dasari
Current oncology reports 23, 1-7, 2021
1942021
Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer
V Morris, MJ Overman, ZQ Jiang, C Garrett, S Agarwal, C Eng, B Kee, ...
Clinical colorectal cancer 13 (3), 164-171, 2014
1442014
A phase II study of the gamma secretase inhibitor RO4929097 in patients with previously treated metastatic pancreatic adenocarcinoma
A De Jesus-Acosta, D Laheru, A Maitra, J Arcaroli, MA Rudek, A Dasari, ...
Investigational new drugs 32, 739-745, 2014
1082014
Pembrolizumab monotherapy in patients with previously treated metastatic high-grade neuroendocrine neoplasms: joint analysis of two prospective, non-randomised trials
N Vijayvergia, A Dasari, M Deng, S Litwin, T Al-Toubah, RK Alpaugh, ...
British journal of cancer 122 (9), 1309-1314, 2020
992020
Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer
AM Sarshekeh, S Advani, MJ Overman, G Manyam, BK Kee, ...
PLoS One 12 (3), e0173345, 2017
952017
Who should get lateral pelvic lymph node dissection after neoadjuvant chemoradiation?
S Malakorn, Y Yang, BK Bednarski, H Kaur, YN You, EB Holliday, ...
Diseases of the Colon & Rectum 62 (10), 1158-1166, 2019
912019
Representativeness of Black patients in cancer clinical trials sponsored by the National Cancer Institute compared with pharmaceutical companies
JM Unger, DL Hershman, RU Osarogiagbon, A Gothwal, S Anand, ...
JNCI Cancer Spectrum 4 (4), pkaa034, 2020
772020
系统目前无法执行此操作,请稍后再试。
文章 1–20